Literature DB >> 29206078

Serological survey of mumps antibodies in adults in the Czech Republic and the need for changes to the vaccination strategy.

Jan Smetana1, Roman Chlibek1, Irena Hanovcova1, Renata Sosovickova1, Libuse Smetanova2, Petra Polcarova1, Peter Gal3, Petr Dite1,4.   

Abstract

Mumps outbreaks, especially in adolescents and young adults, have been reported in the Czech Republic. The aim of the presented study was to determine the seroprevalence of specific IgG antibodies against mumps in the adult population of the Czech Republic. The study was designed as a multicenter serological survey of adults aged 18 years and over. Specific IgG antibodies against mumps were detected in blood samples using an enzyme-linked immunosorbent assay (ELISA). A total of 1,911 serum samples were examined. The overall seropositivity reached 55.3%. In individual age groups, the highest seropositivity 63% (63.5-65.2%) was recorded in adults aged 40 years and over; the lowest seropositivity was found in adults aged 18-29 years (27.4%). The difference in seropositivity rate between the 18-29 years age group and the 40 years and over age groups was statistically significant (p < 0.001). Only the 18-29 years age group included both vaccinated and unvaccinated (born in the pre-vaccine era) individuals. In vaccinated individuals, seropositivity was reported in only 19.1% of persons; in unvaccinated individuals, seropositivity reached 48.2%. Our results demonstrate the long-term persistence of antibodies following natural infection and the decrease in seropositivity that occurs after vaccination over time. This immunity waning may account for the higher susceptibility of adolescents and young adults to mumps. Therefore, the current vaccination program in the Czech Republic could be considered as less effective. It will be modified with the shifting of the second dose of vaccine from two years of age to the preschool age.

Entities:  

Keywords:  Czech Republic; adults; antibodies; mumps; seroprevalence; vaccination program

Mesh:

Substances:

Year:  2018        PMID: 29206078      PMCID: PMC5893213          DOI: 10.1080/21645515.2017.1412021

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  33 in total

1.  Assay of humoral immunity to mumps virus.

Authors:  P A Pipkin; M A Afzal; A B Heath; P D Minor
Journal:  J Virol Methods       Date:  1999-05       Impact factor: 2.014

2.  [Mumps--a reemerging infection? The current incidence of mumps in the East Bohemian region in the Czech Republic].

Authors:  V Stĕpánová; L Plísková; P Kosina; M Splino; M Förstl; R Bolehovská; J Dlhý; M Chrzová
Journal:  Epidemiol Mikrobiol Imunol       Date:  2006-11       Impact factor: 0.444

3.  Mumps virus nomenclature update: 2012.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2012-06-01

4.  An increase in the number of mumps cases in the Czech Republic, 2005-2006.

Authors:  N Boxall; M Kubinyiova; V Príkazský; C Benes; J Cástková
Journal:  Euro Surveill       Date:  2008-04-17

5.  Mumps outbreak in Israel's highly vaccinated society: are two doses enough?

Authors:  E Anis; I Grotto; L Moerman; B Warshavsky; P E Slater; B Lev
Journal:  Epidemiol Infect       Date:  2011-04-20       Impact factor: 2.451

6.  Mumps outbreak in a highly vaccinated student population, The Netherlands, 2004.

Authors:  Heinrich J Brockhoff; Liesbeth Mollema; Gerard J B Sonder; Cees A Postema; Robert S van Binnendijk; Robert H G Kohl; Hester E de Melker; Susan J M Hahné
Journal:  Vaccine       Date:  2010-02-25       Impact factor: 3.641

7.  Mumps increase in Flanders, Belgium, 2012-2013: results from temporary mandatory notification and a cohort study among university students.

Authors:  Toon Braeye; Indra Linina; Rikka De Roy; Veronik Hutse; Magali Wauters; Pia Cox; Ruud Mak
Journal:  Vaccine       Date:  2014-06-25       Impact factor: 3.641

8.  Waning immunity against mumps in vaccinated young adults, France 2013.

Authors:  Sabine Vygen; Aurélie Fischer; Laure Meurice; Ibrahim Mounchetrou Njoya; Marina Gregoris; Bakhao Ndiaye; Adrien Ghenassia; Isabelle Poujol; Jean Paul Stahl; Denise Antona; Yann Le Strat; Daniel Levy-Bruhl; Patrick Rolland
Journal:  Euro Surveill       Date:  2016

9.  Recent resurgence of mumps in the United States.

Authors:  Gustavo H Dayan; M Patricia Quinlisk; Amy A Parker; Albert E Barskey; Meghan L Harris; Jennifer M Hill Schwartz; Kae Hunt; Carol G Finley; Dennis P Leschinsky; Anne L O'Keefe; Joshua Clayton; Lon K Kightlinger; Eden G Dietle; Jeffrey Berg; Cynthia L Kenyon; Susan T Goldstein; Shannon K Stokley; Susan B Redd; Paul A Rota; Jennifer Rota; Daoling Bi; Sandra W Roush; Carolyn B Bridges; Tammy A Santibanez; Umesh Parashar; William J Bellini; Jane F Seward
Journal:  N Engl J Med       Date:  2008-04-10       Impact factor: 91.245

10.  Seroepidemiology of mumps in Europe (1996-2008): why do outbreaks occur in highly vaccinated populations?

Authors:  J Eriksen; I Davidkin; G Kafatos; N Andrews; C Barbara; D Cohen; A Duks; A Griskevicius; K Johansen; K Bartha; B Kriz; G Mitis; J Mossong; A Nardone; D O'Flanagan; F DE Ory; A Pistol; H Theeten; K Prosenc; M Slacikova; R Pebody
Journal:  Epidemiol Infect       Date:  2012-06-12       Impact factor: 4.434

View more
  7 in total

1.  Application of a mixture model to assess the effect of measles-mumps-rubella vaccine on the mumps epidemic in children from kindergarten to early school age in Jiangsu Province, China.

Authors:  Lei Zhang; Zhiguo Wang; Ying Hu; Xiuying Deng; Hongxiong Guo; Xiang Sun; Fenyang Tang; Minghao Zhou; Yuanbao Liu
Journal:  Hum Vaccin Immunother       Date:  2018-06-28       Impact factor: 3.452

2.  Durability of humoral immune responses to rubella following MMR vaccination.

Authors:  Stephen N Crooke; Marguerite M Riggenbach; Inna G Ovsyannikova; Nathaniel D Warner; Min-Hsin Chen; Lijuan Hao; Joseph P Icenogle; Gregory A Poland; Richard B Kennedy
Journal:  Vaccine       Date:  2020-11-12       Impact factor: 3.641

3.  Seroprevalence of measles, mumps, rubella, and varicella zoster virus antibodies among healthcare students: analysis of vaccine efficacy and cost-effectiveness.

Authors:  Í Ödemiş; Ş Köse; Í Akbulut; H Albayrak
Journal:  Rev Esp Quimioter       Date:  2019-10-23       Impact factor: 1.553

4.  Introduction of Two-Dose Mumps-Containing Vaccine into Routine Immunization Schedule in Quzhou, China, Using Cox-Proportional Hazard Model.

Authors:  Zhiying Yin; Canjie Zheng; Quanjun Fang; Xiaoying Gong; Guoping Cao; Junji Li; Ziling Xiang; Wei Song
Journal:  J Immunol Res       Date:  2021-11-05       Impact factor: 4.818

5.  The Concordance between Mumps and Rubella Sero-Positivity among the Israeli Population in 2015.

Authors:  Ravit Bassal; Tamy Shohat; Tal Levin; Rakefet Pando; Eilat Shinar; Doron Amichay; Mira Barak; Anat Ben-Dor; Adina Bar-Haim; Ella Mendelson; Dani Cohen; Lital Keinan-Boker; Victoria Indenbaum
Journal:  Vaccines (Basel)       Date:  2022-06-22

6.  Blood Lead Concentrations and Antibody Levels to Measles, Mumps, and Rubella among U.S. Children.

Authors:  Todd A Jusko; Kyra Singh; Elizabeth A Greener; Marina Oktapodas Feiler; Kelly Thevenet-Morrison; B Paige Lawrence; Robert O Wright; Sally W Thurston
Journal:  Int J Environ Res Public Health       Date:  2019-08-22       Impact factor: 3.390

7.  Long time persistence of antibodies against Mumps in fully MMR immunized young adults: an Italian retrospective cohort study.

Authors:  Francesco Paolo Bianchi; Sara De Nitto; Pasquale Stefanizzi; Angela Maria Vittoria Larocca; Cinzia Annatea Germinario; Silvio Tafuri
Journal:  Hum Vaccin Immunother       Date:  2020-03-18       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.